KalVista Pharmaceuticals (KALV) Operating Income Growth (5y) (2021 - 2025)

KalVista Pharmaceuticals (KALV) Operating Income Growth (5y) (2021 - 2025) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 67,102.16 Bn 67,101.87 Bn -
2 Nanobiotix 1,908.96 Bn 1,908.90 Bn -
3 Akari Therapeutics 959.56 Bn 959.56 Bn -
4 BeOne Medicines 474.03 Bn 469.24 Bn 1.35 Bn
5 Vertex Pharmaceuticals 122.13 Bn 114.88 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 70.09 Bn 61.34 Bn 3.31 Bn
7 Belite Bio 62.34 Bn 62.34 Bn -
8 Argenx Se 55.96 Bn 50.77 Bn 1.41 Bn
9 Alnylam Pharmaceuticals 37.53 Bn 34.52 Bn 959.66 Mn
10 KalVista Pharmaceuticals 1.36 Bn 1.36 Bn 49.41 Mn

Historic Data

Download Data
DateValue
Jul 31, 2025 -32.51%
Apr 30, 2025 -43.78%
Oct 31, 2024 -37.59%
Jul 31, 2024 -35.83%
Apr 30, 2024 -33.89%
Jan 31, 2024 -37.85%
Oct 31, 2023 -43.47%
Jul 31, 2023 -32.93%
Apr 30, 2023 -60.61%
Jan 31, 2023 -44.04%
Oct 31, 2022 -34.24%
Jul 31, 2022 -37.00%
Apr 30, 2022 -39.44%
Jan 31, 2022 -26.87%
Oct 31, 2021 -42.44%
Jul 31, 2021 -30.68%